According to Gram Research analysis, two genetic variants in the CYP24A1 gene (rs1570669 and rs2762934) were not significantly associated with bladder cancer risk in a Turkish population of 330 people. While the A alleles of both variants showed a weak trend toward increased cancer risk, this trend was not statistically significant, meaning it could have occurred by chance. This is the first study examining these variants in a Caucasian population, and larger studies are needed to determine if they play any role in cancer development.
Researchers studied whether two specific genetic variations in the CYP24A1 gene affect bladder cancer risk in Turkish people. The study compared 152 bladder cancer patients with 178 healthy controls to see if these genetic differences, which influence how the body processes vitamin D, played a role in cancer development. While the genetic variants didn’t show a strong connection to bladder cancer risk, the researchers found a weak trend suggesting they might increase risk slightly. This is the first study to examine these particular genetic variations in a Turkish population, adding important information about how genetics may influence cancer susceptibility across different ethnic groups.
Key Statistics
A 2026 case-control study of 330 Turkish adults found that CYP24A1 genetic variants rs1570669 and rs2762934 were not significantly associated with bladder cancer risk, though the A alleles showed a non-significant trend toward increased odds.
In a Turkish population study of 152 bladder cancer patients and 178 healthy controls, vitamin D metabolism-related genetic variants did not significantly predict cancer susceptibility, suggesting other factors may be more important for bladder cancer risk.
A 2026 Turkish case-control study examining 330 participants found that smoking status, age, and body mass index differed significantly between bladder cancer patients and healthy controls, while vitamin D levels did not differ between groups.
The Quick Take
- What they studied: Whether two specific genetic variations in the CYP24A1 gene increase the risk of developing bladder cancer
- Who participated: 330 Turkish adults: 152 people with bladder cancer and 178 healthy people without cancer. The groups were similar in most ways, though they differed in age, body weight, and smoking habits.
- Key finding: The two genetic variants (rs1570669 and rs2762934) were not significantly linked to bladder cancer risk in this Turkish population, though there was a weak trend suggesting the A version of each variant might slightly increase risk.
- What it means for you: These specific genetic variations alone do not appear to be strong predictors of bladder cancer risk in Turkish populations. However, genetics is complex, and these variants may still play a small role when combined with other factors like smoking or environmental exposures. More research in larger groups is needed before drawing firm conclusions.
The Research Details
This was a case-control study, which is a common research method for understanding disease risk. Researchers identified people who already had bladder cancer (the cases) and compared them to similar people without the disease (the controls). They then looked backward to see if genetic differences between the two groups might explain why some people developed cancer.
The researchers used a laboratory technique called TaqMan allelic discrimination assay with real-time PCR to identify which genetic variants each person carried. This method is highly accurate for detecting specific genetic variations. They focused on two particular spots in the CYP24A1 gene, labeled rs1570669 and rs2762934, because these locations are involved in how the body breaks down vitamin D, which plays a role in controlling cell growth.
The study was conducted in Turkey, making it the first investigation of these specific genetic variants in a Turkish (Caucasian) population. Previous research had found these variants might affect cancer risk in Asian populations, so researchers wanted to see if the same pattern held true in a different ethnic group.
Case-control studies are efficient for studying rare diseases like bladder cancer because researchers can quickly find enough affected people to study. By comparing genetic differences between people with and without cancer, researchers can identify which genetic variations might increase disease risk. Understanding genetic risk factors helps doctors identify who might need closer monitoring and could eventually lead to better prevention strategies.
This study used a well-established laboratory method (TaqMan assay) known for accuracy in detecting genetic variations. The sample size of 330 people is reasonable for this type of research. However, the study was limited to one geographic region (Turkey), which means results may not apply to all populations. The researchers were transparent about their limitations and noted that larger studies are needed to confirm their findings. The fact that no significant associations were found suggests the variants may have only weak effects, if any, on bladder cancer risk in this population.
What the Results Show
The study found that neither of the two genetic variants (rs1570669 and rs2762934) showed a statistically significant association with bladder cancer risk in the Turkish population. This means the differences in cancer rates between people with and without these genetic variants could have occurred by chance.
However, the researchers did notice a pattern worth mentioning: people who carried the A version of either genetic variant showed a slight trend toward higher bladder cancer risk, even though this trend was not statistically significant. In research, a trend means the pattern points in one direction but isn’t strong enough to be confident it’s real rather than due to random variation.
The study also found that the two groups (cancer patients and healthy controls) differed in some important ways. People with bladder cancer tended to be older, have higher body mass index (BMI), and were more likely to smoke. These factors are known risk factors for bladder cancer, which makes sense and validates the study design. Interestingly, vitamin D levels did not differ significantly between the two groups, even though the genetic variants studied affect vitamin D metabolism.
The researchers examined whether specific combinations of genetic variants (called genotypes) affected cancer risk differently, but found no significant associations. They also looked at whether the variants had different effects based on age, BMI, or smoking status, but these analyses did not reveal any strong patterns. The lack of secondary findings suggests that if these genetic variants do influence bladder cancer risk, their effect is likely very small or only appears under specific conditions not captured in this study.
Previous research in Asian populations suggested these CYP24A1 variants might increase urinary cancer risk. This Turkish study did not confirm that finding in a Caucasian population. This difference could mean several things: the variants may have different effects in different ethnic groups, the previous studies may have had different results due to chance, or other genetic and environmental factors in different populations may modify how these variants affect cancer risk. The findings highlight the importance of studying genetic risk factors across diverse populations.
The study was limited to people in Turkey, so results may not apply to other populations. The sample size of 330 people, while reasonable, may not be large enough to detect small genetic effects. The study was also limited by its case-control design, which can only show associations, not prove that the genetic variants actually cause cancer. Additionally, the researchers could not account for all possible environmental and lifestyle factors that might influence cancer risk. Finally, the study measured vitamin D levels at one point in time, but vitamin D exposure over a lifetime might be more relevant to cancer risk.
The Bottom Line
Based on this research, these two specific genetic variants should not be used as primary screening tools for bladder cancer risk in Turkish populations. The evidence is not strong enough to recommend genetic testing for these variants as a way to predict cancer risk. However, people with known risk factors for bladder cancer (such as smoking, occupational chemical exposure, or family history) should continue following standard medical screening recommendations regardless of their genetic status. More research in larger populations is needed before any clinical recommendations can be made.
This research is most relevant to people of Turkish or broader Caucasian descent who are concerned about bladder cancer risk. It’s also important for genetic researchers and doctors studying how genetic variations affect cancer susceptibility across different populations. People with a family history of bladder cancer or known risk factors like smoking should focus on established prevention strategies rather than genetic testing for these specific variants. Healthcare providers should be aware of this research when counseling patients about cancer risk.
If these genetic variants do influence bladder cancer risk, the effect would likely develop over many years, as bladder cancer typically takes decades to develop. People cannot expect to see any immediate changes based on knowing their genetic status. Prevention efforts should focus on modifiable risk factors like quitting smoking and reducing exposure to occupational chemicals, which can have benefits within months to years.
Frequently Asked Questions
Do genetic variants in the CYP24A1 gene increase bladder cancer risk?
A 2026 Turkish study of 330 people found that CYP24A1 variants rs1570669 and rs2762934 were not significantly linked to bladder cancer risk, though there was a weak trend suggesting the A alleles might slightly increase risk. Larger studies are needed to confirm whether these variants play any real role.
Should I get genetic testing for bladder cancer risk?
Based on current research, genetic testing for these specific CYP24A1 variants is not recommended for bladder cancer screening. Instead, focus on established risk factors like smoking cessation, staying hydrated, and avoiding occupational chemical exposure. Talk to your doctor about screening if you have a family history of bladder cancer.
How does vitamin D relate to bladder cancer risk?
The CYP24A1 gene controls how the body breaks down vitamin D, which may influence cancer risk. However, a 2026 Turkish study found no significant difference in vitamin D levels between bladder cancer patients and healthy controls, suggesting vitamin D alone may not be a strong predictor of cancer risk.
What are the real risk factors for bladder cancer?
A 2026 study confirmed that smoking, older age, and higher body mass index are associated with bladder cancer risk. Occupational chemical exposure and family history are also known risk factors. These modifiable and non-modifiable factors appear more important than the genetic variants studied.
Can genetic differences between populations affect cancer risk?
Yes, this study was the first to examine these genetic variants in a Turkish population because previous research in Asian populations suggested they might increase cancer risk. The lack of significant association in the Turkish group shows that genetic effects on disease risk can vary across different ethnic populations.
Want to Apply This Research?
- Users could track known bladder cancer risk factors such as smoking status, water intake, occupational chemical exposure, and urinary symptoms. Recording these factors weekly would help identify patterns and motivate behavior change toward established prevention strategies.
- Users should focus on reducing modifiable risk factors rather than worrying about genetic variants. Practical changes include quitting smoking, staying hydrated by drinking adequate water daily, and avoiding occupational chemical exposures when possible. The app could send reminders for these evidence-based prevention strategies.
- Long-term tracking should focus on urinary health indicators and risk factor reduction. Users could log smoking cessation progress, daily water intake, and any urinary symptoms that warrant medical attention. Annual check-ins with healthcare providers remain important for people with risk factors, regardless of genetic status.
This research describes associations between genetic variants and bladder cancer risk in a Turkish population and should not be used for self-diagnosis or to replace professional medical advice. Genetic testing for these specific variants is not currently recommended for clinical use. If you have concerns about bladder cancer risk, family history of cancer, or urinary symptoms, consult with a qualified healthcare provider or urologist. This article summarizes research findings and does not constitute medical advice. Always discuss genetic testing and cancer screening options with your doctor based on your individual risk factors and medical history.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.